Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma
The current study compared the levels and possible associations between systemic soluble immune checkpoints (sICPs, n = 17) and a group of humoral modulators of immune suppressor cells (n = 7) in a cohort of patients with basal cell carcinoma (BCC, n = 40) and a group of healthy control subjects (n...
Main Authors: | Mahlatse C.M. Kgokolo, Nonkululeko Z. Malinga, Helen C. Steel, Pieter W.A. Meyer, Teresa Smit, Ronald Anderson, Bernardo L. Rapoport |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-04-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S193652332300253X |
Similar Items
-
Immune Checkpoint Inhibitors in Cancer Therapy
by: Yavar Shiravand, et al.
Published: (2022-04-01) -
Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
by: Lijun Peng, et al.
Published: (2022-09-01) -
The Role of Immune Checkpoint Inhibitors in Cancer Therapy
by: Ahmed M. Basudan
Published: (2022-12-01) -
Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
by: Pei-Yi Chu, et al.
Published: (2021-10-01) -
The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma
by: Jihyun An, et al.
Published: (2022-03-01)